Results 171 to 180 of about 7,534,152 (213)

Low‐dose X‐ray radiation induces an adaptive response: A potential countermeasure to galactic cosmic radiation exposure

Experimental Physiology, Volume 111, Issue 9, Page 3919-3927, 1 September 2026.
Abstract Space exploration involves many dangers including galactic cosmic radiation (GCR). This class of radiation includes high‐energy protons and heavy ionizing ions. NASA has defined GCR as a carcinogenic risk for long‐duration space missions. To date, no clear strategy has been developed to counter chronic GCR exposure.
Siena Edwards, Jessica Adams, Anastasia Tchernikov, John G. Edwards   +3 more
wiley   +1 more source

ZIP1 Is a Critical DNA Damage‐Responsive Zinc Transporter Induced by Bleomycin via the TNFα–NF‐κB Pathway

The FASEB Journal, Volume 40, Issue 16, 31 August 2026.
The zinc transporter ZIP1 is induced promptly following treatment with the DNA damage agent bleomycin through the TNFα–NF‐κB pathway. NF‐κB accumulates in the nucleus and upregulates the transcription of SLC39A1, the coding gene for ZIP1. The increased expression of ZIP1 leads to elevated intracellular zinc levels, which, in turn, enhance the DNA ...
Zichong Li, Jiajian Yuan, Ziqi Zhang, Hong Huang, Mei Hong   +4 more
wiley   +1 more source

Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials

Annals of Oncology, 2017
Y. El Dakdouki, L. Verlingue, C. Massard, R. Bahleda, A. Hollebecque, L. Mahjoubi, E. Rouleau, L. Lacroix, N. Auger, J.-Y. Scoazec, E. Solary, A. Marabelle, F. André, J.-C. Soria, S. Postel-Vinay   +14 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

European Journal of Medicinal Chemistry, 2022
DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA mutations, which also provides cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies. Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA ...
Jianjun Chen, Xiao Yao, Wei Pan
exaly   +3 more sources

Targeting the DNA damage response (DDR) by natural compounds

Bioorganic and Medicinal Chemistry, 2020
Natural compounds (NC) are an important source of anticancer drugs. The genomic DNA of tumor cells is a major target of conventional anticancer therapeutics (cAT). DNA damage elicits a complex stress response programme termed DNA damage response (DDR), with the PI3-like kinase ATM and ATR being the key regulators.
Jana, van Stuijvenberg, Peter, Proksch, Gerhard, Fritz   +2 more
exaly   +3 more sources

Development of a DNA damage response (DDR) therapeutics platform for oncology.

Journal of Clinical Oncology, 2021
e15036 Background: Cancer cells respond to increases in DNA damage by deploying their DNA damage response (DDR) pathways. We are building a platform for the discovery and development of target-specific DDR therapeutics, including small molecule inhibitors and targeted protein degradation warheads, founded on fragment- and structure-based drug ...
Debanu Das, Matthew Duncton, Patricia Pellicena, Ashley Deacon, David Wilson, Millie Georgiadis   +5 more
openaire   +1 more source

Imaging DNA damage response (DDR) during oncogenesis

Cancer Research, 2016
Introduction: DNA damage repair (DDR) signalling is upregulated during tumorigenesis and acts as a p53-mediated block on proliferation. Expression of the DNA double strand break (DSB) repair protein, γH2AX, is induced by the activated kinases pATM or pATR during oncogenesis. Previously, we showed that γH2AX presents an abundant epitope for non-invasive
Cornelissen, B, Able, S, Kersemans, V, Vallis, K   +3 more
openaire   +1 more source

Interactome Profiling of DNA Damage Response (DDR) Mediators with Immunoprecipitation-Mass Spectrometry

2023
Immunoprecipitation-mass spectrometry (IP-MS) is a versatile tool to probe for global protein-protein interactions (PPIs) in biological samples. Such interactions coordinate complex biological processes, such as the DNA damage response (DDR). Induction of DNA damage activates signaling networks where posttranslational modifications cause PPI that ...
Henry C-H, Law, Dragana, Noe, Nicholas T, Woods   +2 more
openaire   +2 more sources

The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC).

Journal of Clinical Oncology, 2020
4064 Background: Abnormal DDR is a hallmark of cancer, relating to genome instability, anti-tumor immunity, and sensitivity to chemotherapeutic agents and radiation. We conducted a large-scale investigation to clarify the alteration of DDR pathway in CRC. Methods: Tumor samples from 9321 CRC patients were retrospectively reviewed.
Hiroyuki Arai, Andrew Elliott, Jingyuan Wang, Francesca Battaglin, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M. Goldberg, Michael J. Hall, Aaron James Scott, Mohd Khushman, Jimmy J. Hwang, Emil Lou, Benjamin A. Weinberg, John Marshall, Albert Craig Lockhart, Phillip Stafford, Jian Zhang, W. Michael Korn, Heinz-Josef Lenz   +19 more
openaire   +1 more source

Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer

2023
The DNA damage response (DDR) results in activation of a series of key target kinases that respond to different DNA damage insults. DDR inhibitors such as PARP inhibitors lead to the accumulation of DNA damage in tumor cells and ultimately apoptosis. However, responses to DDRi monotherapy in the clinic are not durable and resistance ultimately develops.
Dimitrios, Nasioudis, Erin M, George, Haineng, Xu, Hyoung, Kim, Fiona, Simpkins   +4 more
openaire   +2 more sources